Kefah Mokbel: Should We Review PPIs When Starting a CDK4/6 Inhibitor for Breast Cancer?
Kefah Mokbel/ LinkedIn

Kefah Mokbel: Should We Review PPIs When Starting a CDK4/6 Inhibitor for Breast Cancer?

Kefah Mokbel, Professor of Medicine (Honorary) at Cardiff University School of Medicine, shared on LinkedIn:

“Should we review proton pump inhibitors when starting a CDK4/6 inhibitor for breast cancer?

A nationwide Korean study by Lee and colleagues in The Oncologist raises a practical question for those treating HR-positive, HER2-negative breast cancer.

Among 6,435 patients who remained alive and event-free 90 days after starting a CDK4/6 inhibitor, 574 (8.9%) had received overlapping prescriptions for a proton pump inhibitor (PPI) for at least 30 of those days.

After adjustment, PPI use was associated with shorter real-world progression-free survival (HR 1.33, 95% CI 1.16–1.51) and overall survival (HR 1.54, 95% CI 1.34–1.76).

The study used the start of the next treatment or death as a proxy for progression.

The reason a patient needed a PPI may itself have influenced prognosis, so these findings cannot establish that stopping a PPI improves survival.

What might explain the association?

PPIs raise gastric pH. Palbociclib in capsule form dissolves less readily at higher pH, which can reduce absorption, particularly when taken fasting.

Taking the capsule with food, as prescribed, substantially attenuates this effect.

Formulation matters: in a pharmacokinetic study, rabeprazole had no effect on absorption of the palbociclib tablet, even under fasting conditions. Whether a similar mechanism contributes to poorer outcomes with ribociclib or abemaciclib remains uncertain.

My approach would be to review the indication for the PPI when prescribing a CDK4/6 inhibitor.

For occasional uncomplicated reflux, an as-needed antacid may be sufficient. If there is a compelling indication, such as severe erosive oesophagitis or a high risk of upper gastrointestinal bleeding, I would continue the PPI.

For a patient taking palbociclib who needs ongoing acid suppression, I would also check whether they are receiving capsules and consider the tablet formulation.”

Title: Association of Concomitant Proton Pump Inhibitor Use with Survival Outcomes During CDK4/6 Inhibitor Therapy for Breast Cancer

Authors: Kyung-Hun Lee, Ji Sung Lee, Jeong Eon Lee, Sungmin Park

Read the article

You can also read:

Could Proton Pump Inhibitors Affect Durvalumab Outcomes After Chemoradiotherapy in Stage III NSCLC?

Impact of Proton Pump Inhibitors on Immune Checkpoint Inhibitor Efficacy: Clinical, Microbiome, and Immune Correlates․